the european medicines agency (EMA) has typical an software
to check Sandoz's biosimilar to Amgen's ecu-licensed Neulasta (pegfilgrastim),
a recombinant human granulocyte colony-stimulating issue, Sandoz discern
Novartis stated on Thursday.
Sandoz is searching for popularity of the identical
indication because the reference product, it introduced in a declaration.
The U.S.
meals and Drug management in November widely wide-spread Sandoz's submission
for approval of a biosimilar version of Amgen's Neulasta drug that fights
infections in most cancers patients.
No comments:
Post a Comment